Opinion: Akero and Madrigal Face Off in the MASH Space
While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, Akero Therapeutics is developing what may serve as a viable alternative treatment for precirrhotic disease.
Opinion: Akero and Madrigal Face Off in the MASH Space Read More »
